RXRB and cancer: We demonstrated that RAB39A-RXRB axis plays a prominent role in cancer development and stemness, and that targeting RAB39A and inhibiting its downstream molecular effecter RXRB strongly impairs tumorigenesis and cancer stemness (Figure 5E), with particular regard to musculoskeletal sarcomas and lymphoid malignancies.